Your Top 10 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
Nizar M. Tannir, Laurence K. Albiges, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers and 19 more
- Rank
- 7 of 3,853
- Percentile
- top 0.2%
- Where
- Annals of Oncology, 2024
- Citations
- 230
From the 2024 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.